Aligos Therapeutics, Inc. - Rasio total nilai perusahaan marang pendapatan ALGS

Aligos Therapeutics (ALGS) - logo korporat

Growth prospects depend on FDA verdicts and patient loyalty in hepatitis B therapy. The company's price-to-sales ratio confirms this trend, where the -327.79 mark indicates the current valuation level. Aligos Therapeutics (ALGS) is developing innovative oligonucleotides to combat NASH, diversifying risks through the development of various vaccines and drugs for viral liver pathologies.

Rasio nilai perusahaan marang pendapatan: Aligos (ALGS) kanggo 23.11.2025 - 20.11.2026

Rincian metrik keuangan lan pasar Aligos Therapeutics, Inc. (ALGS)

- rega saham lan prakiraan rega para ahli:
Produk asli aligos.com

Professional managers utilize fundamental filters to distinguish undervalued assets from stagnating companies. This indicator compares the total business value to its annual turnover, excluding the impact of leverage, which allows for a real-time assessment of the market value of Aligos Therapeutics (ALGS) considering its stable substance supply chains; this specific business value-to-revenue trend confirms the effectiveness of production diversification.